Navigation Links
Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
Date:11/5/2009

hapes in both men and women. Each year in the United States alone, there are over 750,000 new cases of ano-genital warts. Treatment options today are limited by tolerability issues such as pain, irritation and swelling at the treatment site. Treatments may include topical preparations, intralesional injection of interferon Alpha-2b and surgically ablative procedures. Helix believes that more effective and better tolerated treatments are needed.

About Topical Interferon Alpha-2b

Interferon Alpha-2b is an immune system modulator that is active against a variety of HPV-induced lesions. Interferon Alpha-2b is thought to function by triggering an antiviral response within infected cells, by activating certain intracellular enzymes which cause degradation of viral RNA, and by mobilizing the body's natural immune system to destroy the infected cells. Interferon Alpha-2b has been widely used commercially as a treatment for ano-genital warts caused by HPV, but is not generally favored due to the fact that conventional administration requires painful intralesional injection by a medical professional. Furthermore, intralesional injection is restricted to visible lesion administration, while HPV infection is often characterized by both visible and non-visible (i.e. sub-clinical) lesions. Helix's Topical Interferon Alpha-2b utilizes the Company's proprietary Biphasix(TM) drug delivery technology, and is expected to offer a safe, discreet, self-administered, pain-free therapy that can be broadly applied across the entire affected tissue area. Helix anticipates that this will prove highly advantageous not only from a patient compliance perspective by offering a superior tolerability profile, but also from an efficacy standpoint.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prev
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Helix BioPharma Corp. Announces Fiscal 2009 Results
2. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
3. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
4. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
5. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
6. Lilly CEO Lechleiter Calls for Repair of the Engine of Biopharma Innovation
7. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
8. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research ... of the "Inhaled Drug Delivery (London, UK - ... This Inhaled Drug Delivery meeting will cover industry ... and much more. The Co-Chairmen are Dr Steven ... , Senior Director, Mylan. Companies participating ...
(Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP ... bellwether trial will commence October 13, 2015. ... the 510K fast-track approval program, Zimmer NexGen knee implant ... only requires that companies provide evidence that the product ... in order to gain permissions. In ...
(Date:9/2/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the Baird 2015 ... . The live presentation takes place on ... presentation will be webcast and may be accessed on ... Listeners are encouraged to visit the website approximately ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
... First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) -, PRINCETON, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... patients six years and older with moderately to,severely active polyarticular ...
... Model Created Using Piecewise Smooth Subdivision Surface Provides Both ... of Fallot Patients, SEATTLE, April 8, 2008 ... and volumetric insights,that help cardiologists diagnose and treat patients ... in the American Journal,Cardiology (2008; Vol. 101, Issue 1, ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3
(Date:9/3/2015)... ... ... types of people who have a hard time gaining weight , it seems that ... those that have a fast metabolism. In order to help those people who have a ... slowing down metabolism. , The first thing to do is to space out meals. When ...
(Date:9/3/2015)... ... , ... James Earl Jones will be hosting an upcoming VOICES IN AMERICA ... will introduce a segment that discusses why it is important for the workplace to ... fostered in any working environment. , Employers are out billions of dollars year after ...
(Date:9/3/2015)... ... September 03, 2015 , ... The partnership will ... and technical support services to promote LodonalTM in Nigeria. The distribution will become ... efficacy and safety of the product. , Managing Director, Fidson Healthcare Plc, Dr ...
(Date:9/2/2015)... ... , ... Leah Binder, MA, MGA, president and CEO of ... will offer the keynote address at the upcoming meeting of the ACO and ... Florida, at the Innisbrook Resort and Golf Club. For an agenda and registration, ...
(Date:9/2/2015)... (PRWEB) , ... September 03, 2015 , ... ... nominations to determine who among America’s policymakers, public servants, activists, corporate executives, entrepreneurs, ... nation’s health care. This year, that process led the magazine to tap the ...
Breaking Medicine News(10 mins):Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3
... need to make tough choice on whether it,s worthwhile, ... Implanted defibrillators don,t seem to provide any particular ... study finds. , A defibrillator can provide a lifesaving ... be fatal. But it generally does nothing for heart ...
... common elective medical proceduresEAGAN, Minn., March 16 Consumers ... quality information through Care Comparison(R), a new online tool ... Minnesota. Care Comparison allows nearly two million Blue Cross ... well as quality, safety and accessibility information for dozens ...
... - Hard to Treat Diseases (HTDS) www.htdsmedical.com ... of investigators (lead by Professor Mirjana Stojiljkovic) from ... Stankovic", University of Belgrade, Serbia, (IBISS group) introduced ... sclerosis (MS), a severe, currently incurable, human disease. ...
... Dr. Eleanor Rogen of the University of Nebraska ... located in Omaha, Nebraska, have identified the triggering ... begin. Preventium http://www.preventium.org is a recently ... risk for breast and prostate cancer. Ercole Cavalieri, ...
... SB 1022/HB 675 Bill Would Provide Access to ... Failure Patients Who QualifyTALLAHASSEE, Fla., March 16 ... Florida) praised Senator Thad Altman and Representative Ritch ... provide access to secondary health insurance for Florida,s ...
... International, Inc.,(Nasdaq: DATA ), a technology and ... trials industry, today announced its operating,results for the fourth ... Revenue for the fourth quarter of 2008 ... period of 2007. Gross profit margin,improved to 80% for ...
Cached Medicine News:Health News:Defibrillator May Not Help Many With Heart Failure 2Health News:Defibrillator May Not Help Many With Heart Failure 3Health News:Blue Cross Puts New Online Shopping Tool in Hands of Consumers 2Health News:Blue Cross Puts New Online Shopping Tool in Hands of Consumers 3Health News:Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple Sclerosis 2Health News:The National Kidney Foundation of Florida Commends Senator Thad Altman, Representative Ritch Workman for Co-Sponsoring 'Common Sense' Legislation Widely Hailed as 'Good for Patients, Good for Taxpayers, Good for Florida' 2Health News:DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008 2Health News:DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008 3Health News:DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008 4Health News:DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008 5Health News:DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008 6Health News:DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008 7Health News:DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008 8Health News:DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008 9Health News:DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008 10
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
IV Prep Swab Sticks are effective, easy to apply, dries quickly and reduces bacterial contaminations. They are ideal for preparation of the skin prior to a ventipuncture or injection....
... Plus Sterile Isopropyl Alcohol ... primarily used as a ... administering injections. They are ... AAMI/ANSI/ISO 11137 standards to ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
Medicine Products: